$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000119312513210938 Filed on May 09, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$140.0K	$1.095M	$1.496M
YoY Change	-90.83%	-26.8%	20.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.740M	$3.990M	$2.320M
YoY Change	69.23%	71.98%	2.65%
% of Gross Profit
Research & Development	$9.564M	$7.127M	$7.246M
YoY Change	26.54%	-1.64%	33.57%
% of Gross Profit
Depreciation & Amortization	$80.00K	$70.00K	$90.00K
YoY Change	0.0%	-22.22%	-47.06%
% of Gross Profit
Operating Expenses	$13.30M	$11.12M	$9.568M
YoY Change	36.13%	16.17%	24.44%
Operating Profit	-$13.16M	-$10.02M	-$8.072M
YoY Change	59.63%	24.13%	25.15%
Interest Expense	$589.0K	$587.0K	$494.0K
YoY Change	30.02%	18.83%	68.6%
% of Operating Profit
Other Income/Expense, Net	$155.0K	$112.0K	-$341.0K
YoY Change	1.97%	-132.84%	-285.33%
Pretax Income	-$13.59M	-$10.49M	-$8.900M
YoY Change	59.13%	17.87%	36.09%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$13.59M	-$10.49M	-$8.895M
YoY Change	59.18%	17.92%	35.97%
Net Earnings / Revenue	-9708.57%	-957.9%	-594.59%
Basic Earnings Per Share
Diluted Earnings Per Share	-$481.9K	-$404.9K	-$396.8K
COMMON SHARES
Basic Shares Outstanding	25.93M shares	25.91M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.10M	$13.30M	$17.60M
YoY Change	175.34%	-24.43%	-59.63%
Cash & Equivalents	$1.716M	$1.716M	$16.80M
Short-Term Investments	$18.30M	$12.00M	$800.0K
Other Short-Term Assets	$500.0K	$500.0K	$400.0K
YoY Change	0.0%	25.0%	33.33%
Inventory
Prepaid Expenses
Receivables	$700.0K	$2.000M	$1.600M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$21.27M	$15.81M	$19.70M
YoY Change	149.66%	-19.72%	-56.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$981.0K	$1.058M	$726.0K
YoY Change	48.64%	45.73%	-65.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$127.0K	$143.0K	$102.0K
YoY Change	44.32%	40.2%	-66.0%
Total Long-Term Assets	$1.787M	$1.880M	$1.391M
YoY Change	15.59%	35.15%	-44.36%
TOTAL ASSETS
Total Short-Term Assets	$21.27M	$15.81M	$19.70M
Total Long-Term Assets	$1.787M	$1.880M	$1.391M
Total Assets	$23.06M	$17.69M	$21.09M
YoY Change	129.07%	-16.1%	-55.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.253M	$2.609M	$2.394M
YoY Change	230.97%	8.98%	49.63%
Accrued Expenses	$4.162M	$6.979M	$5.303M
YoY Change	-30.82%	31.6%	35.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.485M	$997.0K	$6.100M
YoY Change	-59.92%	-83.66%	177.27%
Total Short-Term Liabilities	$10.90M	$10.59M	$18.74M
YoY Change	-36.81%	-43.52%	24.95%
LONG-TERM LIABILITIES
Long-Term Debt	$17.81M	$19.20M	$12.00M
YoY Change	72.9%	60.0%	-33.7%
Other Long-Term Liabilities	$6.600M	$3.800M	$3.100M
YoY Change	120.0%	22.58%
Total Long-Term Liabilities	$17.81M	$19.20M	$15.10M
YoY Change	33.9%	27.15%	-16.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.90M	$10.59M	$18.74M
Total Long-Term Liabilities	$17.81M	$19.20M	$15.10M
Total Liabilities	$28.71M	$29.79M	$33.80M
YoY Change	-6.18%	-11.88%	2.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$238.7M	-$225.1M	-$185.0M
YoY Change	23.29%	21.64%
Common Stock	$298.0K	$259.0K	$225.0K
YoY Change	32.44%	15.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.26M	-$15.86M	-$12.68M
YoY Change
Total Liabilities & Shareholders Equity	$23.06M	$17.69M	$21.09M
YoY Change	129.07%	-16.1%	-55.88%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$13.59M	-$10.49M	-$8.895M
YoY Change	59.18%	17.92%	35.97%
Depreciation, Depletion And Amortization	$80.00K	$70.00K	$90.00K
YoY Change	0.0%	-22.22%	-47.06%
Cash From Operating Activities	-$9.390M	-$8.968M	-$5.505M
YoY Change	5.98%	62.91%	-30.1%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$88.00K	$72.00K
YoY Change	-100.0%	22.22%	-89.44%
Acquisitions
YoY Change
Other Investing Activities	-$6.320M	$8.800M	$19.75M
YoY Change	-870.73%	-55.44%	-2075.0%
Cash From Investing Activities	-$6.310M	$8.707M	$19.68M
YoY Change	-952.7%	-55.75%	-1269.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$16.10M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.14M	$22.00K	-1.376M
YoY Change	-1244.68%	-101.6%	-113.49%
NET CHANGE
Cash From Operating Activities	-9.390M	-$8.968M	-5.505M
Cash From Investing Activities	-6.310M	$8.707M	19.68M
Cash From Financing Activities	16.14M	$22.00K	-1.376M
Net Change In Cash	440.0K	-$239.0K	12.80M
YoY Change	-104.62%	-101.87%	1890.2%
FREE CASH FLOW
Cash From Operating Activities	-$9.390M	-$8.968M	-$5.505M
Capital Expenditures	$0.00	$88.00K	$72.00K
Free Cash Flow	-$9.390M	-$9.056M	-$5.577M
YoY Change	6.95%	62.38%	-34.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25928767	shares
CY2012Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	197478	shares
CY2012Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	12.25
CY2012Q1	omer	Warrant Expiration Date WarrantExpirationDate	2013-03-29
CY2013Q1	omer	Warrant Expiration Date WarrantExpirationDate	2014-03-29
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16802000
CY2012Q4	us-gaap	Loss Contingency Settlement Agreement Consideration1 LossContingencySettlementAgreementConsideration1	3940000
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	494000
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000
CY2013Q1	us-gaap	Incentive From Lessor IncentiveFromLessor	4300000
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	143000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3363267	shares
CY2013Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0925	pure
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-15864000
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9100000
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1559000
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5114000
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	553000
CY2013Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1300000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.65
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5126000
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25910399	shares
CY2013Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	2003000
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2609000
CY2013Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	155000
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-225066000
CY2013Q1	us-gaap	Assets Assets	17693000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.18
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17693000
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	679000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5124000
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1281000
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25910399	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5165630	shares
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6979000
CY2013Q1	us-gaap	Cash Cash	1300000
CY2013Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1832000
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10585000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5356086	shares
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	259000
CY2013Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3772000
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	12035000
CY2013Q1	us-gaap	Assets Current AssetsCurrent	15813000
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	61700000
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1058000
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	997000
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	208943000
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19200000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.09
CY2013Q1	omer	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	1992819	shares
CY2013Q1	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	873000
CY2013Q1	omer	Accrued Contract Research Costs AccruedContractResearchCosts	1368000
CY2013Q1	omer	Accrued Legal Fees AccruedLegalFees	794000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4005000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	416000
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000
CY2012Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0925	pure
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-6531000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	687000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	458000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25897483	shares
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1934000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2632000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	970000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214577000
CY2012Q4	us-gaap	Assets Assets	26575000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.18
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26575000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	679000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1520000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25897483	shares
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5716000
CY2012Q4	us-gaap	Cash Cash	1500000
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	959000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9318000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5390582	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	259000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3685000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1037000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207787000
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20103000
CY2012Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	20830000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	24700000
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1842000
CY2012Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	1447000
CY2012Q4	omer	Accrued Legal Fees AccruedLegalFees	323000
CY2012Q4	omer	Payroll Taxes On Litigation Settlement PayrollTaxesOnLitigationSettlement	13000
CY2012Q4	us-gaap	Insurance Recoveries InsuranceRecoveries	3950000
CY2013Q1	dei	Trading Symbol TradingSymbol	OMER
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10020000
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M26D
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	112000
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10489000
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y11M1D
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1093000
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1227000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.63
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2013Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12916	shares
CY2013Q1	us-gaap	Investment Income Net InvestmentIncomeNet	6000
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	67000
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22000
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8968000
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8707000
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-970000
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.68
CY2013Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-239000
CY2013Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	87000
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3988000
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	75000
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
CY2013Q1	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Organization</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced potential products, which we refer to as products, are derived from our proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our efforts are devoted to conducting research and development of our products, to developing our patent portfolio and to raising equity capital.</font></p> </div>
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7127000
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22000
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	3455000
CY2013Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	41000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	11115000
CY2013Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	120000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	21580	shares
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2013Q1	us-gaap	Revenues Revenues	1095000
CY2013Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	12250000
CY2013Q1	us-gaap	Interest Paid InterestPaid	313000
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25908153	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5965102	shares
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-10489000
CY2013Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	69000
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Use of Estimates</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from those estimates.</font></p> </div>
CY2013Q1	us-gaap	Interest Expense InterestExpense	587000
CY2013Q1	omer	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	41000
CY2013Q1	omer	Lease Extension Period LeaseExtensionPeriod	P5Y
CY2013Q1	omer	Operating Lease Number Of Additional Renewal Option OperatingLeaseNumberOfAdditionalRenewalOption	2	Leases
CY2013Q1	omer	Government Grants Under Review GovernmentGrantsUnderReview	1100000
CY2013Q1	omer	Total Litigation Expense Paid By Insurer TotalLitigationExpensePaidByInsurer	2000000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0106	pure
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8072000
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-341000
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8895000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1131000
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	345000
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2012Q1	us-gaap	Investment Income Net InvestmentIncomeNet	12000
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	93000
CY2012Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M19D
CY2012Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	124000
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5505000
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19678000
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-753000
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72000
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12797000
CY2012Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	3061000
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2322000
CY2012Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1500000
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	326000
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7246000
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1376000
CY2012Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	511000
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	9568000
CY2012Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	103000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.89	pure
CY2012Q1	us-gaap	Revenues Revenues	1496000
CY2012Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	19750000
CY2012Q1	us-gaap	Interest Paid InterestPaid	402000
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22434903	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4776200	shares
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-8895000
CY2012Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	775000
CY2012Q1	us-gaap	Interest Expense InterestExpense	494000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.21
CY2012Q1	omer	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	511000

Files In Submission

Name	View Source	Status
0001193125-13-210938-index-headers.html	Edgar Link	pending
0001193125-13-210938-index.html	Edgar Link	pending
0001193125-13-210938.txt	Edgar Link	pending
0001193125-13-210938-xbrl.zip	Edgar Link	pending
d508095d10q.htm	Edgar Link	pending
d508095dex101.htm	Edgar Link	pending
d508095dex121.htm	Edgar Link	pending
d508095dex311.htm	Edgar Link	pending
d508095dex312.htm	Edgar Link	pending
d508095dex321.htm	Edgar Link	pending
d508095dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
omer-20130331.xml	Edgar Link	completed
omer-20130331.xsd	Edgar Link	pending
omer-20130331_cal.xml	Edgar Link	unprocessable
omer-20130331_def.xml	Edgar Link	unprocessable
omer-20130331_lab.xml	Edgar Link	unprocessable
omer-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2013 Q2 Form 10-Q Financial Statement

#000119312513210938 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2013 Q2 Form 10-Q Financial Statement

#000119312513210938 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer